This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ringe, J. D. Articles by Dorst, A. Search for Related Content PubMed PubMed Citation Articles by Ringe, J. D. Articles by Dorst, A.

Alendronate Treatment of Established Primary Osteoporosis in Men: Results of a 2-Year Prospective Study

Medizinische Klinik 4, Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universität zu Köln, 51375 Leverkusen Germany

Address all correspondence and requests for reprints to: Prof. Dr. Johann D. Ringe, Medizinische Klinik 4, Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universität zu Köln, 51375 Leverkusen Germany.

Abstract

Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men. The bisphosphonate, alendronate, has been widely used for the treatment of postmenopausal osteoporosis. This prospective, open label, active controlled, randomized clinical study compared the effects of oral alendronate (10 mg daily) and alfacalcidol (1 µg daily) on bone mineral density (BMD), safety, and tolerability in 134 males with primary established osteoporosis. All men received supplemental calcium (500 mg daily). After 2 yr, alfacalcidol-treated patients showed a mean 2.8% increase in lumbar spine BMD (P < 0.01) compared with a mean increase of 10.1% in men receiving alendronate (P < 0.001). The corresponding changes in femoral neck BMD were +2.2% and +5.2% for the alfacalcidol and alendronate groups, respectively (P = 0.009). The incidence rates of patients with new vertebral fractures were 18.2% and 7.4% for the alfacalcidol and alendronate groups, respectively (P = 0.071). Both therapies were well tolerated.

Thus, alendronate produced favorable effects on BMD consistent with the results from another study in male osteoporosis. The average increase rates were higher than with alfacalcidol. Alendronate may be superior to alfacalcidol in the treatment of men with established primary osteoporosis.

This article has been cited by other articles:

				P. G Clay, L. E Voss, C. Williams, and E. C Daume Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679. [Abstract] [Full Text] [PDF]

				S. Sharma, M. Fraser, F. Lovell, A. Reece, and A. R. McLellan Characteristics of males over 50 years who present with a fracture: EPIDEMIOLOGY AND UNDERLYING RISK FACTORS J Bone Joint Surg Br, January 1, 2008; 90-B(1): 72 - 77. [Abstract] [Full Text] [PDF]

				M. J. Bolland, A. B. Grey, A. M. Horne, S. E. Briggs, M. G. Thomas, R. B. Ellis-Pegler, A. F. Woodhouse, G. D. Gamble, and I. R. Reid Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1283 - 1288. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, B. Z. Leder, S.-A. M. Burnett, J. J. Wyland, H. Lee, A. V. de la Paz, K. Gibson, and R. M. Neer Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2882 - 2887. [Abstract] [Full Text] [PDF]

				J. K. Amory, N. B. Watts, K. A. Easley, P. R. Sutton, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, and J. L. Tenover Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 503 - 510. [Abstract] [Full Text] [PDF]

				C. A. Thompson, T. D. Shanafelt, and C. L. Loprinzi Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation Oncologist, October 1, 2003; 8(5): 474 - 487. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis N. Engl. J. Med., September 25, 2003; 349(13): 1216 - 1226. [Abstract] [Full Text] [PDF]

				S P Tuck and R M Francis Osteoporosis Postgrad. Med. J., September 1, 2002; 78(923): 526 - 532. [Abstract] [Full Text] [PDF]